The partial virological response to Tenofovir monotherapy in naive patients with chronic hepatitis B

J Pak Med Assoc. 2021 Feb;71(2(A)):550-552. doi: 10.47391/JPMA.1135.

Abstract

We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the department of Infectious Diseases and Clinical microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy.

Keywords: Chronic hepatitis B, Tenofovir, partial response, Entecavir, combination therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • DNA, Viral
  • Drug Therapy, Combination
  • Female
  • Hepatitis B virus / genetics
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Tenofovir / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • DNA, Viral
  • Tenofovir